In Vitro Diagnostics (IVD) include reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. The reagents, instruments and systems are intended for use in the collection, preparation, and examination of specimens taken from the human body. The categories tracked under this market are Cardiac Disease, Hematological Disorders, Hormonal Disorders, Metabolic Disorder, Infectious Disease, IVD Analyzers and Reagents, Oncology and Reproductive Health Diagnostics. Breakpoint Cluster Region- Tyrosine-Protein Kinase ABL1 fusion gene (BCR-ABL) tests are carried out to detect fusion gene mutations in patient tissue samples; the outcome of which may guide therapies to treat various cancers including chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) and acute myelogenous leukemia (AML). GlobalData uses proprietary data and analytics to provide a comprehensive report on the bcr-abl tests market in the US. Buy the latest report here.
In 2022, GlobalData’s Market Model methodology determined that the leading player in the bcr-abl tests market in the US was Abbott Laboratories followed by Agilent Technologies, Bio-Rad Laboratories, Bio-Techne, Danaher, Illumina, Qiagen, Sysmex, Takara Bio and Thermo Fisher Scientific.
Understanding market size can be crucial to evaluate opportunities and make informed decisions about market entry and exit. Medical device companies can identify attractive segments in respective markets as well as develop marketing strategies based on forecasts for those segments.
This market includes BCR-ABL In Situ Hybridization Tests and BCR-ABL Nucleic Acid Amplification Tests (NAATs).
The bcr-abl tests market in the US can expand or contract due to a variety of reasons including population demographics, disease incidence and prevalence, macroeconomic issues, and geopolitical considerations. Disruption to a market could be caused by a sudden, unexpected change in these factors, but it could also be driven by changes in clinical practice, leading to a change in diagnosis or treatment of patients, as part of a process to generally improve medical practice.
For the latest analysis of the market size bcr-abl tests in the US, buy the report here.